On November 17, 2021 Avenue Therapeutics, Inc. (the "Company") (NASDAQ: ATXI), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, reported that the underwriter of its previously announced underwritten public offering has exercised, in full, its option to purchase an additional 292,018 shares of common stock at a price of $1.34 per share (Press release, Avenue Therapeutics, NOV 17, 2021, View Source [SID1234595743]). Total gross proceeds to the Company from the offering, including the funds received from the prior closing and exercise of this option, are approximately $3 million, before deducting underwriting discounts, commissions, and other offering expenses payable by the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aegis Capital Corp. acted as the sole book-running manager for the offering.

The offering was made pursuant to a registration statement on Form S-3 (File No. 333-259850) previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). A final prospectus and accompanying registration statement relating to the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov.

A copy of the final prospectus and accompanying registration statement relating to the offering may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at [email protected], or by telephone at (212) 813-1010.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On November 17, 2021 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, reported that Dr. Garo Armen, Chairman and Chief Executive Officer of Agenus and Dr. Steven O’Day, Chief Medical Officer, will participate in a fireside chat hosted by Evercore on Tuesday, November 30th, 2021 at 1:50 PM EST (Press release, Agenus, NOV 17, 2021, https://investor.agenusbio.com/news-releases/news-release-details/agenus-participate-4th-annual-evercore-isi-healthconx-conference [SID1234595742]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Registration can be completed in advance at: View Source

A replay will be available after the call on the Events & Presentations page of the Agenus website at View Source

On November 17, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, reported that Rick Pauls, President and CEO, will participate in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will also be available for one-on-one meetings (Press release, DiaMedica, NOV 17, 2021, View Source [SID1234595741]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A recording of the presentation will be available beginning on Monday, November 22, 2021, at 10:00a.m. Eastern Time. Interested parties may access the presentation in the "Investors" section of the company’s website at View Source

On November 17, 2021 Odonate Therapeutics, Inc. (NASDAQ: ODT) reported that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders (Press release, Odonate Therapeutics, NOV 17, 2021, View Source [SID1234595740]). This action is in connection with the Company’s previously announced decision to discontinue the development of tesetaxel. Repurchases may be made from time to time at the Company’s discretion. The plan has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of September 30, 2021, as reported in its recently filed Form 10-Q, the Company had total stockholders’ equity of $71.4 million, or $1.85 per share, based on 38.5 million shares outstanding.

On November 17, 2021 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the Company’s synthetic lethal PRMT5 inhibitor, MRTX1719, for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers (Press release, Mirati, NOV 17, 2021, View Source [SID1234595739]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MRTX1719 has demonstrated in preclinical studies to be a potent, selective inhibitor of the PRMT5 / methylthioadenosine (MTA) complex. This targeting strategy leverages the abnormally elevated levels of MTA present in MTAP-deleted cancers. As a result, MRTX1719 is able to selectively target the essential PRMT5 protein in MTAP-deleted cancer cells while sparing healthy non-tumor cells. MTAP gene deletions occur in approximately 10% of all cancers including pancreatic, lung, and bladder cancers, as well as other patient populations that have limited treatment options. Preclinical data for MRTX1719 were first presented at the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC Virtual International Conference.

"We are excited to take this next step in the advancement of MRTX1719 to clinical trials," said James Christensen, Ph.D., chief scientific officer, Mirati Therapeutics, Inc. "MRTX1719 was discovered and developed internally at Mirati, representing an important milestone for the Company’s continued expansion of its pipeline and further reinforcing our differentiated end-to-end drug discovery and development capabilities. We look forward to further evaluating MRTX1719 as a potentially best-in-class treatment for patients living with MTAP-deleted cancers."

The Phase 1/2 clinical development strategy for MRTX1719 is designed to establish a Phase 2 dose and assess the safety, pharmacokinetics and initial clinical activity of MRTX1719 in patients with MTAP-deleted cancers. The Company expects to initiate a Phase 1/2 clinical trial in the first quarter of 2022, pending IND clearance from the FDA.